. 2018 Jun 26;10:1749–1761. doi: 10.2147/CMAR.S160452

Table 2.

AUCs for immune molecules and in combination with CA15-3 in breast cancer

Parameters	Breast cancer (total)			Early-stage breast cancer (N = 44)			Advanced breast cancer (N = 47)
Parameters	AUC	95% CI	P	AUC	95% CI	P	AUC	95% CI	P
PD-1	0.764	0.674–0.855	<0.001^*	0.761	0.654–0.869	<0.001^*	0.725	0.614–0.837	0.001^*
CTLA-4	0.695	0.594–0.796	0.001^*	0.698	0.580–0.817	0.004^*	0.687	0.568–0.807	0.006^*
FOXP3	0.642	0.540–0.744	0.021^*	0.652	0.528–0.775	0.028^*	0.611	0.485–0.736	0.104
TGF-β	0.712	0.610–0.815	0.001^*	0.706	0.587–0.825	0.003^*	0.703	0.585–0.820	0.003^*
IL-10	0.743	0.646–0.840	<0.001^*	0.730	0.616–0.844	0.001^*	0.738	0.628–0.849	<0.001^*
IL-2Rα	0.758	0.668–0.849	<0.001^*	0.756	0.647–0.866	<0.001^*	0.740	0.629–0.851	<0.001^*
CD28	0.703	0.603–0.803	0.001^*	0.711	0.595–0.828	0.002^*	0.672	0.551–0.793	0.012^*
CA15-3	0.707	0.613–0.800	0.001^*	0.607	0.477–0.737	0.121	0.791	0.688–0.893	<0.001^*
PD-1 + CA15-3	0.847	0.778–0.916	<0.001^*	0.780	0.677–0.883	<0.001^*	0.880	0.802–0.959	<0.001^*
IL-10 + CA15-3	0.835	0.76–0.91	<0.001^*	0.764	0.656–0.873	<0.001^*	0.891	0.821–0.960	<0.001^*
IL-2Rα + CA15-3	0.841	0.769–0.912	<0.001^*	0.783	0.680–0.886	<0.001^*	0.875	0.797–0.954	<0.001^*
PD-1 + IL-10 + CA15-3	0.859	0.791–0.926	<0.001^*	0.799	0.700–0.898	<0.001^*	0.896	0.826–0.965	<0.001^*
PD-1 + IL-2Rα + CA15-3	0.854	0.786–0.921	<0.001^*	0.792	0.692–0.891	<0.001^*	0.883	0.806–0.960	<0.001^*
IL-10 + IL-2Rα + CA15-3	0.860	0.791–0.928	<0.001^*	0.805	0.706–0.903	<0.001^*	0.893	0.824–0.962	<0.001^*
PD-1 + IL-10 + IL-2Rα +	0.862	0.795–0.929	<0.001^*	0.811	0.713–0.910	<0.001^*	0.896	0.827–0.964	<0.001^*
CA15-3

Note:

P<0.05.

Abbreviations: AUC, area under curve; CA15-3, cancer antigen 15-3; PD-1, programmed cell death 1; CTLA-4, cytotoxic T lymphocyte antigen 4; FOXP3, forkhead box P3; TGF-β, transforming growth factor-beta; IL-10, interleukin-10; IL-2Rα, interleukin-2 receptor alpha; CD28, cluster of differentiation 28.